Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (121-130 of 432) with videos related to

Pageof 44
Sort By:
Oncogene|March 1, 2005
Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitroValérie Soenen-Cornu, Cristina Tourino, Marie-Laure Bonnet, et al.
Blood|October 11, 2007
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical studySimone Boehrer, Lionel Adès, Thorsten Braun, et al.
European Journal of Haematology|April 17, 2010
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*Valeria Santini, Pierre Fenaux, Ghulam J Mufti, et al.
British Journal of Haematology|January 4, 2012
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agentsDavid Sibon, Giovanna Cannas, Fiorenza Baracco, et al.
Genes, Chromosomes & Cancer|August 31, 2012
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletionAmel Sebaa, Lionel Ades, Fanny Baran-Marzack, et al.
Oncotarget|February 11, 2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyThomas Prebet, Andrea Toma, Thomas Cluzeau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2006
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter studyNorbert Vey, Andre Bosly, Agnes Guerci, et al.
Occupational and Environmental Medicine|September 15, 2010
Occupational exposure to organic solvents and lymphoid neoplasms in men: results of a French case-control studyLaurent Orsi, Alain Monnereau, Brigitte Dananche, et al.
Haematologica|October 7, 2017
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromesThomas Cluzeau, Kathy L McGraw, Brittany Irvine, et al.
Cancer|June 10, 2011
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromesLewis R Silverman, Pierre Fenaux, Ghulam J Mufti, et al.
Pageof 44

Showing results (121-130 of 432) with videos related to

Sort By:
Pageof 44
Oncogene|March 1, 2005
Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitroValérie Soenen-Cornu, Cristina Tourino, Marie-Laure Bonnet, et al.
Blood|October 11, 2007
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical studySimone Boehrer, Lionel Adès, Thorsten Braun, et al.
European Journal of Haematology|April 17, 2010
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*Valeria Santini, Pierre Fenaux, Ghulam J Mufti, et al.
British Journal of Haematology|January 4, 2012
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agentsDavid Sibon, Giovanna Cannas, Fiorenza Baracco, et al.
Genes, Chromosomes & Cancer|August 31, 2012
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletionAmel Sebaa, Lionel Ades, Fanny Baran-Marzack, et al.
Oncotarget|February 11, 2017
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyThomas Prebet, Andrea Toma, Thomas Cluzeau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2006
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter studyNorbert Vey, Andre Bosly, Agnes Guerci, et al.
Occupational and Environmental Medicine|September 15, 2010
Occupational exposure to organic solvents and lymphoid neoplasms in men: results of a French case-control studyLaurent Orsi, Alain Monnereau, Brigitte Dananche, et al.
Haematologica|October 7, 2017
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromesThomas Cluzeau, Kathy L McGraw, Brittany Irvine, et al.
Cancer|June 10, 2011
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromesLewis R Silverman, Pierre Fenaux, Ghulam J Mufti, et al.
Pageof 44